Clinical Trial Update: A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study evaluating Sativex in combination with dose-intense temozolomide for recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Sativex (nabiximol)
• temozolomide (dose-intense) (temozolomide)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED